Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/180762
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mitjà Villar, Oriol | - |
dc.contributor.author | Corbacho-Monné, Marc | - |
dc.contributor.author | Ubals, Maria | - |
dc.contributor.author | Alemany Ortiz, Andrea | - |
dc.contributor.author | Suñer Navarro, Clara | - |
dc.contributor.author | Tebé, Cristian | - |
dc.contributor.author | Tobias, Aurelio | - |
dc.contributor.author | Peñafiel, Judith | - |
dc.contributor.author | Ballana, Ester | - |
dc.contributor.author | Pérez, Carla A. | - |
dc.contributor.author | Admella, Pol | - |
dc.contributor.author | Riera-Martí, Núria | - |
dc.contributor.author | Laporte, Pep | - |
dc.contributor.author | Mitjà, Jordi | - |
dc.contributor.author | Clua, Mireia | - |
dc.contributor.author | Bertran, Laia | - |
dc.contributor.author | Sarquella, Maria | - |
dc.contributor.author | Gavilán, Sergi | - |
dc.contributor.author | Ara, Jordi | - |
dc.contributor.author | Argimón Pallás, José M. | - |
dc.contributor.author | Cuatrecasas, Gabriel | - |
dc.contributor.author | Cañadas, Paz | - |
dc.contributor.author | Elizalde Torrent, Aleix | - |
dc.contributor.author | Fabregat, Robert | - |
dc.contributor.author | Farré Albaladejo, Magí | - |
dc.contributor.author | Forcada, Anna | - |
dc.contributor.author | Flores Mateo, Gemma | - |
dc.contributor.author | López, Cristina | - |
dc.contributor.author | Muntada, Esteve | - |
dc.contributor.author | Nadal, Núria | - |
dc.contributor.author | Narejos, Silvia | - |
dc.contributor.author | Nieto, Aroa | - |
dc.contributor.author | Prat, Núria | - |
dc.contributor.author | Puig, Jordi | - |
dc.contributor.author | Quiñones, Carles | - |
dc.contributor.author | Ramírez-Viaplana, Ferran | - |
dc.contributor.author | Reyes Urueña, Juliana Maria | - |
dc.contributor.author | Riveira-Muñoz, Eva | - |
dc.contributor.author | Ruiz, Lidia | - |
dc.contributor.author | Sanz, Sergi | - |
dc.date.accessioned | 2021-10-21T13:16:57Z | - |
dc.date.available | 2021-10-21T13:16:57Z | - |
dc.date.issued | 2021-02-04 | - |
dc.identifier.issn | 0028-4793 | - |
dc.identifier.uri | http://hdl.handle.net/2445/180762 | - |
dc.description.abstract | Background: current strategies for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are limited to nonpharmacologic interventions. Hydroxychloroquine has been proposed as a postexposure therapy to prevent coronavirus disease 2019 (Covid-19), but definitive evidence is lacking. Methods: we conducted an open-label, cluster-randomized trial involving asymptomatic contacts of patients with polymerase-chain-reaction (PCR)-confirmed Covid-19 in Catalonia, Spain. We randomly assigned clusters of contacts to the hydroxychloroquine group (which received the drug at a dose of 800 mg once, followed by 400 mg daily for 6 days) or to the usual-care group (which received no specific therapy). The primary outcome was PCR-confirmed, symptomatic Covid-19 within 14 days. The secondary outcome was SARS-CoV-2 infection, defined by symptoms compatible with Covid-19 or a positive PCR test regardless of symptoms. Adverse events were assessed for up to 28 days. Results: the analysis included 2314 healthy contacts of 672 index case patients with Covid-19 who were identified between March 17 and April 28, 2020. A total of 1116 contacts were randomly assigned to receive hydroxychloroquine and 1198 to receive usual care. Results were similar in the hydroxychloroquine and usual-care groups with respect to the incidence of PCR-confirmed, symptomatic Covid-19 (5.7% and 6.2%, respectively; risk ratio, 0.86 [95% confidence interval, 0.52 to 1.42]). In addition, hydroxychloroquine was not associated with a lower incidence of SARS-CoV-2 transmission than usual care (18.7% and 17.8%, respectively). The incidence of adverse events was higher in the hydroxychloroquine group than in the usual-care group (56.1% vs. 5.9%), but no treatment-related serious adverse events were reported. Conclusions: postexposure therapy with hydroxychloroquine did not prevent SARS-CoV-2 infection or symptomatic Covid-19 in healthy persons exposed to a PCR-positive case patient. (Funded by the crowdfunding campaign YoMeCorono and others; BCN-PEP-CoV2 ClinicalTrials.gov number, NCT04304053.). | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Massachusetts Medical Society | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1056/NEJMoa2021801 | - |
dc.relation.ispartof | New England Journal of Medicine, 2021, vol. 384, num. 5, p. 417-427 | - |
dc.relation.uri | https://doi.org/10.1056/NEJMoa2021801 | - |
dc.rights | (c) Massachusetts Medical Society, 2021 | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Agents antiinfecciosos | - |
dc.subject.classification | Ús terapèutic | - |
dc.subject.classification | COVID-19 | - |
dc.subject.other | Anti-infective agents | - |
dc.subject.other | Therapeutic use | - |
dc.subject.other | COVID-19 | - |
dc.title | A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19 | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 715041 | - |
dc.date.updated | 2021-10-21T13:16:57Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33289973 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
715041.pdf | 543.57 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.